
Study Period | 2019 - 2030 |
Base Year For Estimation | 2024 |
Market Size (2025) | USD 65.74 Billion |
Market Size (2030) | USD 84.30 Billion |
CAGR (2025 - 2030) | 5.10 % |
Fastest Growing Market | North America |
Largest Market | North America |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Diabetes Care Devices Market Analysis
The Diabetes Care Devices Market size is estimated at USD 65.74 billion in 2025, and is expected to reach USD 84.30 billion by 2030, at a CAGR of 5.1% during the forecast period (2025-2030). Key drivers fuelling the expansion of the diabetes devices market include increasing diabetes prevalence, heightened adoption of cost effective diabetes devices including insulin pens, glucose monitors, etc, and enhanced healthcare access for the general public. Further, type 1 diabetes arises from an immune system malfunction, whereas type 2 diabetes is associated with a sedentary lifestyle, leading to insulin resistance. Thus, type 1 diabetes is classified as insulin-requiring, while type 2 diabetes is termed insulin-dependent.
Global healthcare industry faces a significant challenge from the rising incidence of diabetes cases. For example, as per the International Diabetes Federation (IDF) 2024 update, 540 million people are living with diabetes across the globe. Looking ahead to 2045, projections from the IDF indicate a worrying trend; 1 in 8 adults, totaling around 783 million, will be diagnosed with diabetes, marking a 46% rise. Such escalating instances offer significant insights for diabetes care devices market analysis.
Digital health apps that not only display and summarize individual blood glucose measurements but also integrate relevant data like insulin doses, meals, and physical activity, are paving the way for enhanced self-management. These innovations alleviate the disease burden and elevate the standard of diabetes care. Moreover, the fusion of blood glucose monitoring with tools like insulin calculators, automated insulin titration software, and remote coaching offers crucial support to patients grappling with poorly controlled diabetes. For instance, as per the article published in January 2024 in the American Diabetes Association Journal, devices like the Omnipod 5, an automated insulin delivery (AID) system, are categorized under hybrid closed-loop (HCL) insulin delivery technologies. It comprises a tubeless pod insulin pump that wirelessly connects to a Dexcom G6 continuous glucose monitoring (CGM) sensor via Bluetooth. The system employs a control algorithm to adjust insulin delivery in real time based on glucose levels and is complemented by a mobile app featuring an integrated bolus calculator. Such advancements not only promise to uplift critical health outcomes but also bolster the market's prospects in the coming years.
Moreover, government initiatives and recommendations to undergo diabetes testing and continuous monitoring on time are set to boost market growth during the forecast period. For instance, every year on November 14, World Diabetes Day plays a pivotal role in amplifying global awareness about diabetes, a pressing public health issue affecting millions around the globe. In November 2024, the theme ‘Breaking Barriers, Bridging Gaps’ highlighted the urgent need for accessible, high-quality diabetes care, particularly for marginalized communities. The Government of India adopts a proactive, multi-faceted strategy to combat diabetes, focusing on improved healthcare access, awareness campaigns, and lifestyle promotion. Through these efforts, the government seeks to not only diminish the prevalence of diabetes but also mitigate its long-term complications, paving the way for a healthier future for all citizens, which ultimately drives the market growth over the forecast period.
In summary of this industry analysis, the rising prevalence of diabetes, coupled with an increasing demand for diabetes care devices, is driving the market's expansion. The high costs associated with advanced diabetic care devices could hinder the market's growth trajectory during the forecast period.
Diabetes Care Devices Market Insights and Trends
The Continuous Glucose Monitoring Segment is Expected to Witness a Healthy Growth Rate as per this Market Forecast
The continuous glucose monitoring under the monitoring devices segment is expected to have the fastest growth rate with a CAGR of 12.89% over the forecast period (2024-2029). Market research estimates that the continuous glucose monitoring segment is expected to have a market value of 11.63 billion in 2024 and is likely to reach a market value of USD 21.32 billion by 2029.
CGMs provide real-time updates on blood glucose (sugar) levels through a body-attached device. Over the years, their rising popularity and enhanced accuracy have established them as a credible treatment choice for individuals with diabetes.
Numerous research studies underscore the significance of CGM, suggesting robust growth for the segment in the coming years. For instance, as per the article published in September 2024 in the Journal of Managed Care & Specialty Pharmacy, the researchers mentioned that the National Committee for Quality Assurance recognized the Glucose Management Indicator, a continuous glucose monitoring (CGM) metric, as a viable alternative to hemoglobin A1c for gauging diabetes control. This pivotal decision underscores the growing acknowledgment of diverse CGM metrics in evaluating diabetes status. Hence, such recommendations are expected to bolster the segment growth over the forecast period.
Moreover, the emerging continuous glucose monitoring devices can either download data to retrospectively show blood glucose trends or provide real-time glucose readings via receiver displays. For instance, in August 2024, Medtronic plc, a global frontrunner in healthcare technology, secured FDA approval for its Simplera continuous glucose monitor (CGM). This marks Medtronic's debut in the realm of disposable, all-in-one CGMs, and the Simplera is notably half the size of its predecessors. Its discreet design streamlines the insertion process and enhances the wear experience, eliminating the need for overtape. With the integration of new technologies, continuous glucose monitoring devices are becoming more affordable, a trend expected to fuel segment growth in the coming years.

The Disposable Pens Segment Held the Highest Growth Rate in this Market
By management devices, the disposable pens segment held the highest growth rate, with an estimated market size of USD 33.31 billion in 2024, and it is expected to witness a CAGR of 3.40% over the forecast period (2024 - 2029). Market analysis indicates it will grow to USD 39.36 billion by 2029. Disposable pens in diabetes devices are gaining significant popularity due to their convenience, ease of use, and cost-effectiveness, providing patients with a more comfortable and hygienic alternative for insulin administration, while helping to ensure accurate and consistent dosing.
The diabetes care devices market is segmented into management devices and monitoring devices. The management segment is further segmented into insulin pumps, insulin syringes, insulin cartridges, disposable pens, and jet injectors. The insulin pumps are further segmented into insulin pump device insulin pump reservoirs and infusion sets. The monitoring devices are further bifurcated into devices that self-monitor blood glucose and monitor continuous glucose. The self-monitoring blood glucose is further segmented into glucometer devices, test strips, and lancets. The continuous glucose monitoring segment is further segmented into sensors and durables. Segmenting the management devices and monitoring devices enables stakeholders to grasp market dynamics and pinpoint key growth opportunities.
North America is Expected to Dominate the Diabetes Care Devices Market During the Forecast Period
By geography, the North American region is likely to hold a major share with an estimated market size of USD 27.52 billion in 2024, expected to reach USD 37.19 billion by 2029, with a CAGR of 6.21%. In North America, the diabetes devices market is fueled by a growing geriatric population, heightened patient awareness regarding the diabetic devices that are primarily used for glucose monitoring and patient care, and an uptick in diabetic cases across countries like the United States, Canada, and Mexico.
The rising incidence of diabetic cases is significantly boosting the demand for cost-effective glucose monitoring systems to understand patients' varying glucose levels. For instance, as per the report published by Diabetes Canada in October 2024, 5.8 million people were living with diabetes in 2024 and this number is likely to be increased to 7.3 million in 2034. Hence, owing to the high number of diabetes cases, the demand for diabetic care medical devices increases, leading to regional growth over the forecast period.
Furthermore, growing government initiatives and increased regulatory approvals for insulin delivery devices in the region are expected to drive market growth. For instance, in April 2023, the United States Food and Drug Administration approved Medtronic’s MiniMed 780G System, which automates insulin delivery, assisting individuals aged 7 and above in managing diabetes. It continuously monitors glucose levels, detects trends, and tracks patterns. Based on this data, the system utilizes an insulin pump to automatically administer and adjust insulin dosages as required. Hence, considering the approvals of advanced diabetic care devices offers significant market opportunities for emerging players in North America, ultimately driving the market growth over the forecast period.
As a result, regulatory product approvals, coupled with a rise in diabetes cases, are expected to drive market growth in the region during the forecast period.
By geography, the global market is segmented into North America (United States, Canada, rest of North America), Europe (France, Germany, Italy, Spain, United Kingdom, Russia, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Latin America (Mexico, Brazil, Rest of Latin America), Asia-Pacific (Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Rest of Asia-Pacific), Middle East and Africa (Saudi Arabia, Iran, Egypt, Oman, South Africa, Rest of Middle East and Africa). Countries such as China, Japan, and India are at the forefront of rapidly advancing both the development of sophisticated diabetic care devices and the burgeoning market demand in the Asia-Pacific region. This region prioritizes establishing response systems and advanced diabetic care devices to tackle emerging diabetic cases.

Diabetes Care Devices Industry Overview
The market is semi-consolidated and consists of global and local players. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares. Key players in the diabetes care devices market research include Abbott Diabetes Care, Roche Diabetes Care, Dexcom, Medtronic, Novo Nordisk, LifeScan, Ascensia Diabetes Care, AgaMatrix, Bionime Corporation, Insulet Corporation, Medisana, Ypsomed, Trivida, Rossmax International Ltd., among others.
In terms of market share, few of the major players currently dominate the market. Market leaders and key players are at the forefront of developing CGM systems, test strips, and other diabetic care devices for diabetes. For example, in February 2024, DexCom Inc., a leading key player in real-time continuous glucose monitoring (CGM) for diabetics, introduced its latest CGM system, the Dexcom ONE+, across Spain, Belgium, Poland, and the Netherlands. Consequently, product launches are fueling segment growth by meeting crucial demands like enhanced accuracy, convenience, and user-friendliness in diabetes management. These launches underscore companies' commitment to innovation, aiming to boost patient outcomes and solidify their foothold in the competitive diabetes care device market. This move is poised to drive market growth during the forecast period.
Diabetes Care Devices Market Leaders
-
Novo Nordisk
-
Abbott
-
Dexcom
-
Medtronic
-
Roche
- *Disclaimer: Major Players sorted in no particular order

Diabetes Care Devices Market News
- November 2024: DexCom, Inc., a global frontrunner in glucose biosensing, teamed up with ŌURA, the creator of the premier smart ring, to forge a strategic alliance. This collaboration aims to empower millions and enhance their metabolic health. By merging Dexcom's glucose insights with ŌURA's data on vital signs, sleep patterns, stress levels, heart health, and physical activity, users of both platforms will gain a holistic view of their health.
- September 2024: Abbott launched its inaugural over-the-counter glucose sensor in the United States, following closely on the heels of Dexcom's introduction of the competitive product. Dubbed Lingo, the device is designed for wellness monitoring, targeting individuals without diabetes. It's accessible to those aged 18 and above who aren't insulin users.
- August 2024: DexCom, Inc., launched its over-the-counter glucose biosensor, Stelo, in the United States. The product delivers round-the-clock, tailored glucose insights straight to the smartphone, highlighting the impacts of food, exercise, and sleep on glucose levels.
- March 2024: Roche announced encouraging topline results for its groundbreaking continuous glucose monitoring (CGM) solution in Italy. The system features a CGM sensor paired with two specialized apps, which display real-time glucose levels and provide predictive insights for the next 30 minutes and two hours.
Diabetes Care Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD Billion)
-
5.1 Monitoring Devices
- 5.1.1 Self-monitoring Blood Glucose
- 5.1.1.1 Glucometer Devices
- 5.1.1.2 Test Strips
- 5.1.1.3 Lancets
- 5.1.2 Continuous Glucose Monitoring
- 5.1.2.1 Sensors
- 5.1.2.2 Durables
-
5.2 Management Devices
- 5.2.1 Insulin Pumps
- 5.2.1.1 Insulin Pump Device
- 5.2.1.2 Insulin Pump Reservoir
- 5.2.1.3 Infusion Set
- 5.2.2 Insulin Syringes
- 5.2.3 Insulin Cartridges
- 5.2.4 Disposable Pens
- 5.2.5 Jet Injectors
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Rest of North America
- 5.3.2 Europe
- 5.3.2.1 France
- 5.3.2.2 Germany
- 5.3.2.3 Italy
- 5.3.2.4 Spain
- 5.3.2.5 United Kingdom
- 5.3.2.6 Russia
- 5.3.2.7 Rest of Europe
- 5.3.3 Latin America
- 5.3.3.1 Mexico
- 5.3.3.2 Brazil
- 5.3.3.3 Rest of Latin America
- 5.3.4 Asia-Pacific
- 5.3.4.1 Japan
- 5.3.4.2 South Korea
- 5.3.4.3 China
- 5.3.4.4 India
- 5.3.4.5 Australia
- 5.3.4.6 Vietnam
- 5.3.4.7 Malaysia
- 5.3.4.8 Indonesia
- 5.3.4.9 Philippines
- 5.3.4.10 Thailand
- 5.3.4.11 Rest of Asia-Pacific
- 5.3.5 Middle East and Africa
- 5.3.5.1 Saudi Arabia
- 5.3.5.2 Iran
- 5.3.5.3 Egypt
- 5.3.5.4 Oman
- 5.3.5.5 South Africa
- 5.3.5.6 Rest of Middle East and Africa
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Abbott Diabetes Care
- 7.1.2 Roche Diabetes Care
- 7.1.3 Dexcom
- 7.1.4 Medtronic
- 7.1.5 Novo Nordisk
- 7.1.6 LifeScan
- 7.1.7 Ascensia Diabetes Care
- 7.1.8 AgaMatrix
- 7.1.9 Bionime Corporation
- 7.1.10 Insulet Corporation
- 7.1.11 Medisana
- 7.1.12 Ypsomed
- 7.1.13 Trivida
- 7.1.14 Rossmax International Ltd.
- *List Not Exhaustive
-
7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Self-monitoring Blood Glucose Devices
- 7.2.1.1 Abbott Diabetes Care
- 7.2.1.2 Roche Diabetes Care
- 7.2.1.3 LifeScan
- 7.2.2 Continuous Glucose Monitoring Devices
- 7.2.2.1 Dexcom
- 7.2.2.2 Medtronic
- 7.2.2.3 Abbott Diabetes Care
- 7.2.3 Insulin Devices
- 7.2.3.1 Insulet Corporation
- 7.2.3.2 Novo Nordisk
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Diabetes Care Devices Industry Segmentation
As per the scope of the report, Diabetes care devices are the hardware, equipment, and software used by diabetes patients to regulate blood glucose levels, prevent diabetes complications, lessen the burden of diabetes, and enhance the quality of life.
The diabetes care devices market is segmented into management devices and monitoring devices and geography. The management segment is further segmented into insulin pumps, insulin syringes, insulin cartridges, disposable pens, and jet injectors. The insulin pumps are further segmented into insulin pump device insulin pump reservoirs and infusion sets. The monitoring devices are further bifurcated into devices that self-monitor blood glucose and monitor continuous glucose. The self-monitoring blood glucose is further segmented into glucometer devices, test strips, and lancets. The continuous glucose monitoring segment is further segmented into sensors and durables The geography is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America. The report offers the value (in USD Billion) and volume (in Unit) for the above segments. Further, the report will cover a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.
Monitoring Devices | Self-monitoring Blood Glucose | Glucometer Devices | |
Test Strips | |||
Lancets | |||
Continuous Glucose Monitoring | Sensors | ||
Durables | |||
Management Devices | Insulin Pumps | Insulin Pump Device | |
Insulin Pump Reservoir | |||
Infusion Set | |||
Insulin Syringes | |||
Insulin Cartridges | |||
Disposable Pens | |||
Jet Injectors | |||
Geography | North America | United States | |
Canada | |||
Rest of North America | |||
Europe | France | ||
Germany | |||
Italy | |||
Spain | |||
United Kingdom | |||
Russia | |||
Rest of Europe | |||
Latin America | Mexico | ||
Brazil | |||
Rest of Latin America | |||
Asia-Pacific | Japan | ||
South Korea | |||
China | |||
India | |||
Australia | |||
Vietnam | |||
Malaysia | |||
Indonesia | |||
Philippines | |||
Thailand | |||
Rest of Asia-Pacific | |||
Middle East and Africa | Saudi Arabia | ||
Iran | |||
Egypt | |||
Oman | |||
South Africa | |||
Rest of Middle East and Africa |
Diabetes Care Devices Market Research FAQs
How big is the diabetes care devices market?
The diabetes care devices market size is estimated at USD 65.74 billion in 2025 and is expected to reach USD 84.30 billion by 2030, growing at a CAGR of 5.10% during the forecast period (2025-2030).
What is the future outlook for the diabetes devices market?
Closed-loop systems are evolving, integrating Continuous Glucose Monitors (CGMs) with insulin pumps. This advancement is refining automated insulin delivery, similar to an "artificial pancreas," which modulates insulin in response to real-time glucose fluctuations. Further, mobile health applications are set to experience rapid growth, enhancing patient engagement and self-management strategies in diabetic care.
How is technology, such as AI and IoT, impacting diabetes care devices?
Healthcare professionals are increasingly leveraging AI to enhance diabetes management, employing predictive analytics, fine-tuning insulin delivery, and tailoring patient care. With IoT-enabled devices, patients can monitor their glucose levels continuously and non-invasively, significantly boosting their comfort and commitment to treatment.
What are the challenges and opportunities in the diabetes care devices market?
The high costs of many advanced devices restrict their accessibility, particularly in developing regions. Technological advancements, including minimally invasive devices and digital health solutions, are underscoring significant opportunities in patient engagement and monitoring.
Who are the major players in the diabetes devices market?
The major players in the diabetes care devices market are Dexcom, Medtronic, Abbott, Novo Nordisk, Eli Lilly, etc., and other regional players.